Latest News Releases From The Newsroom
SEC Charges Investment Adviser and Principal in Abusive Naked Short Selling Scheme
June 12th, 2023
FOR IMMEDIATE RELEASE 2023-107 Washington D.C. / CRWE PRESS RELEASE / June 12, 2023 — The Securities and Exchange Commission today charged investment adviser Sabby Management LLC and its managing partner, Hal D. Mintz, with fraud in c. Read more
Triple Impact: iBio's Collaboration, Oracle's Strong Q4, and EVgo's Charging Network Growth Make Waves
June 12th, 2023
iBio, Inc. (NYSE American: IBIO) has partnered with the National Institute of Allergy and Infectious Diseases (NIAID) to explore the potential of the company's AI-driven epitope steering platform in developing a vaccine for Lassa fever, a severe and . Read more
Nasdaq Is To Takeover Adenza, Catalent Reports Q3 Loss: Market Updates
June 12th, 2023
Nasdaq, Inc. (Nasdaq: NDAQ) has announced a definitive agreement to acquire Adenza, a leading provider of risk management and regulatory software to the financial services industry, from Thoma Bravo for a total consideration of $10.5 billion in cash . Read more
Alvotech, Teva, JNJ Settle on AVT04; Teck Resources Evaluating Glencore Proposal
June 12th, 2023
Alvotech (Nasdaq: ALVO) and an affiliate of Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) have announced a settlement and license agreement with Johnson & Johnson (NYSE: JNJ) concerning AVT04, Alvotech's proposed biosimilar to Stelara (ustekinumab. Read more
Keybanc Sees Opportunity On AMD, AppFolio, AvidXchange, and Ameren
June 12th, 2023
Advanced Micro Devices, Inc. (Nasdaq: AMD), a leading semiconductor company specializing in advanced computing and graphics technologies, saw its price target raised by KeyBanc from $110 to $150. With $AMD closing at $124.92 on Friday, this . Read more
Pharvaris: Potential On-Demand HAE Treatment; Novartis Is To Takeover Chinook Therapeutics
June 12th, 2023
Pharvaris N.V. (Nasdaq: PHVS) released data from their Phase 2 study, RAPIDe-1, evaluating the on-demand treatment of hereditary angioedema (HAE) attacks with PHVS416 (deucrictibant immediate-release capsules). The study showed that treatment with. Read more
Intellia Therapeutics and Ocular Therapeutix: Promising Trial Data for HAE and Wet AMD
June 11th, 2023
Intellia Therapeutics, Inc. (Nasdaq: NTLA) has shared updated interim results from the Phase 1 portion of their ongoing study of NTLA-2002, a CRISPR candidate for treating hereditary angioedema (HAE). The company believes that the data reinf. Read more
Quarterly Results Ahead: Adobe, Kroger, Jabil, and Cognyte Reports Coming
June 10th, 2023
Thursday, June 15, will see several companies releasing their financial results, including: Adobe Inc. (Nasdaq: ADBE), a global leader in digital media and marketing solutions, is set to announce its second-quarter fiscal year 2023 results after t. Read more
Earnings Figures Preview: Lennar, Anterix, Aurora Cannabis, and High Tide
June 10th, 2023
Several companies are expected to report their financial results on Wednesday, June 14, including: Lennar Corporation (NYSE: LEN)(NYSE:LEN.B), a leading home construction and real estate development company, is set to announce its second-qua. Read more
Biogen: FDA Panel Backs OK of Alzheimer's Drug; Disc Medicine: Upgraded, Promising Trial Data
June 10th, 2023
Eisai and Biogen's (Nasdaq: BIIB) Alzheimer's drug candidate, LEQEMBI (lecanemab-irmb), received unanimous support from FDA PCNS panel based on Phase 3 Clarity AD trial data. The committee acknowledged its clinical benefit, overall benefit-r. Read more
Want To Find Some News?
News By Industries
Recent Posts
-
Earnings Countdown: PepsiCo, WD-40, Simply Good Foods in Focus
July 05th, 2026
Member Login